Skip to content

Lilly and Hims & Hers Offer Zepbound and Foundayo at Self-Pay Prices Starting at $149 and $299

November 7, 2026 · 10 min

Show notes

Eli Lilly and Hims & Hers announced an agreement on November 6, 2026, to expand access to FDA-approved Zepbound (tirzepatide) and Foundayo (orforglipron) through the Hims & Hers telehealth platform. Eligible patients who receive a prescription from a licensed provider on the platform can get the medicines at Lilly's self-pay prices without leaving the platform, with home shipment after consultation. Self-pay pricing starts at $149 per month for Foundayo and $299 per month for Zepbound. Hims & Hers has never offered compounded copies of Lilly's GLP-1s and committed not to do so; the companies also said they will protect independent clinical decision-making. The arrangement puts Lilly on similar footing with Novo Nordisk's earlier branded-access deal with Hims & Hers.

Sources

This episode is for information only and is not medical advice. Always talk to your doctor before starting, stopping, or changing any medication.

Visit glp1newspaper.com for today's stories and free email alerts.

All episodes of GLP-1 Newspaper: Daily Ozempic, Zepbound & Weight-Loss Drug News

Settings

Display

Language

Decides which stations you see first on the home page.

History

Recently played stations and episodes and your latest searches are only stored in this browser.

Notifications

A short notice when a podcast you follow has a new episode. Turn off single podcasts with the bell on their page.

Account

Save favorites – in the app and on the website.

Keyboard shortcuts

/
Open search
Space
Play or pause
← →
In the player: back 15 s, forward 30 s (episodes) · in a row: next tile
↑ ↓
In a row: target within the tile
Home / End
In a row: first or last tile
Esc
Close window or menu
?
This overview
Now playing

Go to station page

Play next

    Add episodes with “Play next” – they play after the current episode.